Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Warner-Lambert describes NK2 antagonists for obesity

Oct. 18, 1996

Antiobesity proteins described by Lilly

Oct. 18, 1996

Anorexigenic dihydropyridine compounds from Bristol-Myers Squibb

Oct. 18, 1996

Lilly claims compounds for women's health

Oct. 18, 1996

Atosiban efficacy in treating preterm labor

Oct. 11, 1996

Yamanouchi awaits marketing approval for new contraceptive

Oct. 11, 1996

Improved formulation of Testoderm available in U.S.

Oct. 11, 1996

Muse approvable for treatment of impotence

Oct. 11, 1996

Aldose reductase inhibitor in phase III at Fujisawa

Oct. 11, 1996

Antidiabetic agents from Yamanouchi's clinical pipeline

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...